MDXXF (Pharmala Biotech Holdings) General and Admin. Expense: $1.31 Mil (TTM As of Feb. 2026)


MDXXF Pharmala Biotech Holdings Inc MDXXF
35 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharmala Biotech Holdings General and Admin. Expense?

Pharmala Biotech Holdings MDXXF +7.74% 35 General and Admin. Expense is $1.31 Mil as of Feb. 2026. GuruFocus rates MDXXF with a GF Score™ of 35/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Pharmala Biotech Holdings's General and Admin. Expense for the three months ended in Feb. 2026 was $0.34 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 was $1.31 Mil.

Pharmala Biotech Holdings General and Admin. Expense Related Terms

Pharmala Biotech Holdings General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings General and Admin. Expense Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
General and Admin. Expense
1.96 0.71 0.86 0.88 1.54

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.35 0.33 0.29 0.34
MDXXF
35GF Score
Pharmala Biotech Holdings Inc MDXXF
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $1.31 Mil mean?
Pharmala Biotech Holdings (MDXXF) has a General and Admin. Expense of $1.31 Mil as of Feb. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' General and Admin. Expense too high?
Pharmala Biotech Holdings' current General and Admin. Expense is $1.31 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' General and Admin. Expense compare to VRTX and REGN?
Pharmala Biotech Holdings' General and Admin. Expense of $1.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current General and Admin. Expense is $1.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current General and Admin. Expense is $1.31 Mil. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current General and Admin. Expense is $1.31 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • General and Admin. Expense: $1.31 Mil
  • GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score

Get the complete analysis for MDXXF

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value